1. Home
  2. PED vs BOLD Comparison

PED vs BOLD Comparison

Compare PED & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

HOLD

Current Price

$13.54

Market Cap

206.2M

Sector

Energy

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.42

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PED
BOLD
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
206.2M
36.5M
IPO Year
2012
2024

Fundamental Metrics

Financial Performance
Metric
PED
BOLD
Price
$13.54
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$30.00
$4.00
AVG Volume (30 Days)
24.0K
129.1K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$45,751,000.00
N/A
Revenue This Year
$171.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.67
N/A
52 Week Low
$0.43
$0.96
52 Week High
$18.89
$1.68

Technical Indicators

Market Signals
Indicator
PED
BOLD
Relative Strength Index (RSI) 46.62 46.18
Support Level $13.09 $1.40
Resistance Level $16.24 $1.53
Average True Range (ATR) 0.73 0.06
MACD -0.09 -0.01
Stochastic Oscillator 28.23 26.92

Price Performance

Historical Comparison
PED
BOLD

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: